Search

Your search keyword '"Biagio, Antonio Di"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Biagio, Antonio Di" Remove constraint Author: "Biagio, Antonio Di"
48 results on '"Biagio, Antonio Di"'

Search Results

1. Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.

2. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.

4. 1949. Evaluation of cellular and humoral immune-responses at different times after SARS-COV-2 vaccination in health care workers cohort

5. Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia

6. Off-label use of combined antiretroviral therapy, analysis of data collected by The Italian Register for HIV-1 infection in Paediatrics in a large cohort of children.

7. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males

8. The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The “ImpACT-COVID-19 for Patients” Multi-Centre Observational Study

9. Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy.

10. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19

11. Clofazimine: an old drug for never-ending diseases

13. Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study.

15. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19.

16. Additional file 1: of How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy

17. Additional file 1: of Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study

19. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.

20. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.

21. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

23. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

24. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates

25. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.

29. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

30. Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

33. Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir

37. Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

38. 96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience.

39. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study.

40. Benign Lymphoepithelial Parotid Lesions in Vertically HIV-Infected Patients.

41. The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research.

42. Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

43. Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy.

44. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.

45. A first update on mapping the human genetic architecture of COVID-19

46. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

47. Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy

48. Distinct features of immune activation and exhaustion markers in people with perinatally-acquired HIV.

Catalog

Books, media, physical & digital resources